AKT1 and cardiovascular disorder: Notably, Akt-MSCs have an enhanced cell survival ratio with augmented expression levels of ERK and VEGF, suggesting that administering Akt-transduced MSCs might be a promising therapeutic strategy for treating human patients with cardiovascular diseases.